🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses

RecruitingNAAges 18 Years - anyAllMontefiore Medical Center
NCT07631598 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring them to community buprenorphine treatment providers. Buprenorphine is a medication that helps reduce opioid cravings and withdrawal symptoms. The study compares two ways of connecting people to treatment: Referral to a community treatment provider (usual care before the new program begins). Onsite, low-threshold buprenorphine treatment at the SSP, which allows participants to start medication quickly and without having to establish care at another provider. Participants will be adults who have opioid use disorder and are SSP clients. Each SSP will begin offering the new onsite buprenorphine program at different times during the study. Researchers will collect information before and after t

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. ≥ 18 years old; 2. Meet DSM-5 criteria for moderate or severe OUD; 3. Interest in receiving buprenorphine treatment; 4. Speaks English or Spanish; 5. Currently an SSP client at the time of enrollment; 6. Ability to provide informed consent. Exclusion Criteria: 1. Current use of prescribed opioid agonist treatment, as assessed by self-report, at the time of enrollment; 2. Unstable mental health or medical condition that requires an immediate clinical evaluation or higher level of care; 3. Allergy to buprenorphine; 4. Currently detained in jail, prison, residential substance use treatment facility, or other overnight facility as required by court of law. or have pending legal action that could prevent participation on study activities.
💊

What it tests

  • Standard of Care Referral
  • Low Threshold Buprenorphine
📍

Where

8 sites
Community Health Project Los Angeles (CHPLA)
Los Angeles, United States
HIPS
Washington D.C., United States
CARPBR/Be Safe Syringe Program
Baton Rouge, United States
Harm Reduction Sisters
Duluth, United States
Alianza of New Mexico
Roswell, United States
HIV Alliance
Grants Pass, United States
Challenges, Inc/Prisma Health
Greenville, United States
Vivent Health
Milwaukee, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy